Sunday, November 22, 2026
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEANFastest Growing
Fiinews
No Result
View All Result
Home Manufacturing

Manufacturing: CCI approves BSV acquisition by Mankind

Fiinews by Fiinews
October 3, 2024
in Manufacturing
Reading Time: 1 min read
A A
0
Mankind
0
SHARES
17
VIEWS
LinkedinShare on Twitter

BSV markets biological, biotech and pharmaceutical products

Competition Commission of India (CCI) has approved the acquisition of Bharat Serums and Vaccines Limited (BSV) by Mankind Pharma Ltd which develops, manufactures, and markets a diverse range of pharmaceutical finished dosage formulations (FDFs) across various acute and chronic therapeutic areas, as well as several consumer healthcare products such as condoms, emergency contraceptives, pregnancy tests, vitamins, minerals, nutrients, antacids and anti-acne preparations segments.

The proposed transaction involves the acquisition of 100% shareholding of BSV by Mankind, a public listed company which through its subsidiaries is also engaged in, inter alia, the manufacture and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediaries, and packaging products for pharmaceutical products.

BSV, along with its subsidiaries, is engaged in research, development, licensing, manufacturing, importing, exporting, marketing and distribution of: (a) FDFs and APIs; (b) biotech and biological formulations and/or API; (c) food and health supplements; (d) medical devices; and (e) ayurvedic medicines; in each case, in the therapeutic areas such as gynaecology, in-vitro fertilisation, critical care and/or emergency medicines for human use.

In India, the activities of BSV (including its wholly owned Indian subsidiary, BSV Pharma Private Limited, which is in the process of merging with BSV) are limited to developing, manufacturing, and marketing a range of biological, biotech, and pharmaceutical products in the therapeutic areas of women’s health, critical care, IUI-IVF, and emergency medicine, CCI said on 2 Oct 2024. Fiinews.com

Tags: CCI
ShareTweetShare

Related Posts

PIB
Manufacturing

Manufacture: BRIC aims for $1trn bioeconomy by 2047

by Fiinews
November 22, 2026
0
15

Scientific achievements must translate into technologies, products and solutions, says Minister The integration of biotechnology research institutions under the Biotechnology...

PIB
Manufacturing

Manufacture: Paswan wants value in agriculture products

by Fiinews
November 22, 2026
0
17

Industry encouraged to develop healthier beverage alternatives, including millets and indigenous ingredients Minister of Food Processing Industries Chirag Paswan has...

Vikram Solar

Manufacture: TN facility to produce from Dec 2026

November 16, 2026
18
ISNT

Manufacture: Minister wants strengthened NDT ecosystem

November 17, 2026
18
NITI Aayog

Manufacture: PLI successful, says NITI Aayog

November 14, 2026
17
Zetsol

Manufacture: 22 bids received for ACC facilities

November 14, 2026
22
SBI YONO

Recent News

  • Tender: PM inaugurates projects in Vaishali
  • Manufacture: BRIC aims for $1trn bioeconomy by 2047
  • Export: Ministers review 6th round of CEPA in Delhi
  • Market: Greaves expands global marine business
  • Market: Polycab strengthens presence in US

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY
  • About
  • Advertise
  • Careers
  • Contact us

© 2026 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
  • ASEAN

© 2026 FIINEWS - Design and developed by 7clicksmedia.